69222-61-3

Usage

Uses

Used in Pharmaceutical Industry:
2H-Cyclopenta[b]furan-2-one, hexahydro-4-(hydroxymethyl)-5-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3aR,4S,5R,6aS)is used as a pharmaceutical intermediate for the synthesis of novel drug candidates. Its unique molecular structure and heterocyclic nature make it a promising candidate for the development of new therapeutic agents with potential applications in treating various diseases and medical conditions.
Used in Medical Experimental Research:
In the field of medical experimental research, 2H-Cyclopenta[b]furan-2-one, hexahydro-4-(hydroxymethyl)-5-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3aR,4S,5R,6aS)serves as a valuable compound for studying the properties and mechanisms of action of furan heterocyclic derivatives. Its synthesis and modification can provide insights into the development of new drugs and therapeutic strategies, contributing to the advancement of medical science and healthcare.

InChI:InChI=1/C13H20O5/c14-7-9-8-5-12(15)17-10(8)6-11(9)18-13-3-1-2-4-16-13/h8-11,13-14H,1-7H2/t8-,9-,10+,11-,13?/m1/s1

Upstream product

• 32233-41-3 (3aR,4R,5R,6aS)-hexahydro-2-oxo-5-<(tetrahydro-2H-pyran-2-yl)oxy>-2H-cyclopentafuran-4-carboxaldehyde 
• 110-87-2 3,4-dihydro-2H-pyran 
• 32233-40-2 (3aR,4S,5R,6aS)-5-hydroxy-4-(hydroxymethyl)hexahydro-2H-cyclopenta[b]furan-2-one 
• 58707-50-9 (3aR,4S,5R,6aS)-4-((tert-butyldimethylsilyloxy)methyl)-5-hydroxyhexahydro-2H-cyclopenta[b]furan-2-one 
• 65025-95-8 (3aR,4S,5R,6aS)-4-({[dimethyl(2-methyl-2-propanyl)silyl]oxy}methyl)-5-(tetrahydro-2H-pyran-2-yloxy)hexahydro-2H-cyclopenta[b]furan-2-one 
• 62447-84-1 (3aR,4S,5S,6R,6aR)-4-Benzyloxymethyl-6-iodo-5-(tetrahydro-pyran-2-yloxy)-hexahydro-cyclopenta[b]furan-2-one 
• 31767-37-0 6-Benzyloxymethyl-7-hydroxy-8-iodo-2-oxabicyclo<3.3.0>octan-3-one 
• 114647-67-5 (3R,1'R)-5-(1'-carboxy-3'-methylbutoxy)imino-3-hydroxy-1-cyclopentene-1-acetic acid methyl ester 
• 53813-10-8 (3aR,4S,5R,6aS)-4-Nitromethyl-5-(tetrahydro-pyran-2-yloxy)-hexahydro-cyclopenta[b]furan-2-one 
• 947752-04-7 [(R)-5-Oxo-3-(tetrahydro-pyran-2-yloxy)-cyclopent-1-enyl]-acetic acid methyl ester 
• 114716-07-3 (R)-2-methoxycarbonylmethyl-4-hydroxy-2-cyclopenten-1-one 
• 88147-21-1 2-methoxycarbonylmethyl-4-hydroxy-2-cyclopenten-1-one 
• 57026-61-6 5-oxo-1-cyclopenten-1-acetic acid methyl ester 
• 32233-38-8 3α,5α-dihydroxy-2β-(benzyloxymethyl)cyclopentane-1α-acetic acid γ-lactone 3-tetrahydropyran-2-yl ether 

Downstream Products

• 32233-40-2 (3aR,4S,5R,6aS)-5-hydroxy-4-(hydroxymethyl)hexahydro-2H-cyclopenta[b]furan-2-one 
• 65025-95-8 (3aR,4S,5R,6aS)-4-({[dimethyl(2-methyl-2-propanyl)silyl]oxy}methyl)-5-(tetrahydro-2H-pyran-2-yloxy)hexahydro-2H-cyclopenta[b]furan-2-one 
• 876068-08-5 7-[(1R,2R,3R)-2-(4,4-difluoro-3-oxooctyl)-5-oxo-3-(2-tetrahydropyranyloxy)cyclopentyl]heptanoic acid 
• 333963-40-9 lubiprostone 
• 773825-80-2 7,7-difluoro-16S,20-dimethyl-18,19-didehydro prostaglandin I₂ 
• 1262874-46-3 4-{(5aR,6R,7R,8aS)-7-hydroxy-6-[(1E,3R)-3-hydroxy-4-phenoxy-1-buten-1-yl]-5,5a,6,7,8,8a-hexahydro-2H-cyclopenta[b]oxepin-3-yl}butanoic acid 
• 1262874-45-2 3-{(5aR,6R,7R,8aS)-7-hydroxy-6-[(1E,3R)-3-hydroxy-4-phenoxy-1-buten-1-yl]-5,5a,6,7,8,8a-hexahydro-2H-cyclopenta[b]oxepin-3-yl}propanoic acid 

Relevant academic research and scientific papers

The preparation method of the ruby's forefront

The invention relates to a preparation method of lubiprostone, and concretely relates to a preparation method of highly pure lubiprostone represented by formula (I). The method comprises the steps of reducing an initial compound, oxidizing, and hydrolyzing in order to obtain a target compound. Compared with other methods, the method provided by the invention has the advantages of good process reappearance, simple operation, high yield, low cost, high purity of the above obtained product, suitableness for industrialized production, and very high economic benefit.

Transformation of δ-lactone in γ-lactone in the Corey route for synthesis of prostaglandins

(Un)substituted benzoate ester protected δ-lactone alcohols are alcoholized in acid catalysis in almost quantitative yield to hydroxyl-halogenoesters. For alkylesters the yield drops to ～70%. After changing the protection between primary and secondary alcohols, the intermediate halogenoesters are transformed into the known γ-lactone alcohols protected as ether, silyl-ether or trityl at the secondary alcohol group. Unprotected δ-lactone alcohol 1 is also quantitatively transformed in chloroester 20. After selective protection of the primary alcohol with bulky ether groups, this is finally transformed into the known Corey γ-lactone alcohol, protected as ester at the secondary alcohol.

METHOD FOR TREATING SCHIZOPHRENIA

The present invention provides a novel fatty acid derivative. The present invention also provides use of an effective amount of a fatty acid derivative for treating schizophrenia in a mammalian subject.

Synthesis of corey lactone via highly stereoselective asymmetric diels-alder reaction

We have succeeded in a highly stereoselective asymmetric Diels-Alder reaction between a chiral acrylate 3a derived from commercially available D-pantolactone 2 and 5-benzyloxymethyl-cyclopentadiene 4 to give the adduct 5a in 94% d.e. and 79% yield for the synthesis of Corey lactone 1.

STEREOSPECIFIC NITROMETHANE CONJUGATE ADDITION TO 4-OXYGENATED-2-SUBSTITUTED-CYCLOPENT-2-ENONES: A SIMPLE APPROACH TO PROSTAGLANDINS

The compatibility of nitromethane conjugate addition to 2-cyclopentenones bearing a 4-oxygenated function has been illustrated through a short and practical synthesis of the Corey aldehyde, a key intermediate in prostaglandin synthesis, in both racemic and optically active form.A new synthesis of PGF2α featuring the introduction of the ω-chain via cycloaddition has been also described.